Development of Bivalent mRNA Vaccines against SARS-CoV-2 Varinats
Previous：EV71-CA16 BIVALENT HFMD VACCINE CANDIDATE OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Next：FREEZE-DRIED HUMAN RABIES VACCINE CANDIDATE (SERUM-FREE VERO CELL) OBTAINED THE CLINICAL TRIAL APPROVAL ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
